昭衍新藥(603127.SH)：刊發境外上市外資股發行聆訊後資料集
格隆匯 2 月 1日丨昭衍新藥(603127.SH)公佈，2021年1月28日，香港聯交所上市委員會舉行上市聆訊，審議了公司本次發行上市的申請。具體內容詳見公司於2021年1月30日披露在中國證監會指定的信息披露網站巨潮資訊網的《關於香港聯交所審議公司發行境外上市外資股的公吿》。
根據此次發行上市的時間安排，公司按照有關規定在香港聯交所網站刊登聆訊後資料集。該聆訊後資料集為公司根據香港聯交所、香港證券及期貨事務監察委員會的要求而刊發，刊發目的僅為提供資訊予香港公眾人士，除此以外並無任何其他目的，公司對聆訊後資料集及其內容也不負有任何義務或責任。同時，該聆訊後資料集為草擬版本，其所載資料並不完整，亦可能會適時作出更新和變動。
鑑於聆訊後資料集的刊發目的僅為提供信息予香港公眾人士，公司將不會在境內或香港以外的任何其他地區的信息披露媒體及監管機構指定的信息披露網站上刊登聆訊後資料集，但為使境內投資者及時瞭解該聆訊後資料集披露的公司的相關信息，該聆訊後資料集可在香港聯交所網站的以下網址進行查閲：
中文：https://www1.hkexnews.hk/app/sehk/2020/102741/documents/sehk21013100085_c.pdf
英文：https://www1.hkexnews.hk/app/sehk/2020/102741/documents/sehk21013100086.pdf
需要特別予以説明的是，該公吿僅為境內投資者及時瞭解公司的相關信息而作出。公司不會通過該公吿或刊登於香港聯交所網站的聆訊後資料集向任何個人或實體發行或出售任何證券；該公吿以及聆訊後資料集不構成也不得視作對任何個人或實體收購、購買或認購公司任何證券的要約或要約邀請。由於聆訊後資料集的發佈受到法律限制，任何個人或實體必須在遵守相關法律法規的前提下才可查閲該聆訊後資料集。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
